Issue link: https://www.e-digitaleditions.com/i/1521797
Inhalation June 2024 33 pMDI development for low GWP propellants RxPack is a global leader in pharmaceutical dispens- ing solutions and drug delivery systems. Specializing in pMDIs, the company manufactures a compre- hensive valve portfolio for formulation solutions and suspensions. As the inhalation community develops pressurized metered dose inhalers (pMDIs) that uti- lize propellants with lower global warming potential (GWP), there is a need for aerosol valves compatible with those gases. In collaboration with the Univer- sity of Parma, RxPack has presented scientific papers demonstrating robustness and suitability of its pre- mium pMDI valves with key formulations such as beclometasone solution using HFA-152a and salbu- tamol suspension associated with HFO-1234ze. Fur- ther information can be made available upon request at sales@rxpack.it. RxPack S.r.l. Italy: +39 034118960 sales@rxpack.it www.rxpack.eu DPI development and manufacturing services Experic's experienced team provides customized and scalable filling, packaging and logistics solutions at clinical- and commercial-scale for reservoir and single-dose dry powder inhalation (DPI) devices. From early development and manufacturing for any single- dose unit, to clinical trial supplies and logistics, Experic offers services that can solve dry powder inhaler manufacturing challenges, acceler- ate time to market, and mitigate risk for products with a range of properties, particle sizes, doses and throughput requirements. Experic LLC US: +1 609 537-4040 www.expericservices.com www.inhalationmag.com Designed to provide educational content, the Inhalation 1-2-3 e-newsletter includes a supplier's perspective on industry issues, highlights technical articles from the magazine and previews industry conferences. Please watch for it in your inbox every other month. Sign up now by emailing your name, company name and email address to subscriptions@inhalationmag.com.